Peer-influenced content. Sources you trust. No registration required. This is HCN.

Trending Topics:
DIET & NUTRITION PATIENT EDUCATION OBESITY/WEIGHT MANAGEMENT EXERCISE/TRAINING LEGAL MATTERS GUIDELINES/RECOMMENDATIONS

Articles related to TYROSINE KINASE INHIBITOR (TKI)

Retinal Physician

Axpaxli Superior to Aflibercept in Wet AMD Trial

“Axpaxli is the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti-VEGF agent since their initial approval more than 20 years ago.” — Pravin U. Dugel, MD, Ocular Therapeutix

Ophthalmology March 9th 2026

Tags: AGE-RELATED MACULAR DEGENERATION (AMD) RESEARCH & CLINICAL TRIALS RETINA TYROSINE KINASE INHIBITOR (TKI)

Topics

Sources

American Journal of Clinical Pathology (AJCP)
American Nurse Journal (ANJ)
Anesthesiology News
Annals of Internal Medicine
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cardiology Advisor
Cleveland Clinic Journal of Medicine (CCJM)
Clinical Advisor
Conexiant
Consultant360
Cureus
Dermatology Advisor
Endocrinology Advisor
Gastroenterology Advisor
GoodRx for Healthcare Professionals
Healthgrades for Professionals
Hematology Advisor
JNP: The Journal for Nurse Practitioners
Journal of Invasive Cardiology (JIC)
Journal of the American College of Cardiology (JACC)
Journal of the National Cancer Institute (JNCI)
Mayo Clinic
MD Newsline
MDLinx
MedCentral
Medical News Today (MNT)
Medical Professionals Reference (MPR)
Neurology Advisor
Oncology News Central (ONC)
Ophthalmology Advisor
Pharmacy Practice News
Physician’s Weekly
Practical Neurology
Psychiatrist.com
Psychiatry Advisor
ReachMD
Renal & Urology News
The American Journal of Nursing (AJN)
UCLA Health
WebMD
Women’s Healthcare
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form